Inventor · disambiguated record
Peter Smith
Also filed as: SMITH PETER · SMITH PETER G · SMITH PETER GERARD
16 granted patents·34 pending applications·25 citations·filing 2012–2024
89Inventor score
Top patents by PatentIndex Score
50 records- 0186US2025135017A1Splicing modulator antibody-drug conjugates and methods of useEISAI R&D MAN CO LTD·Filed 2024·Application pending·0 cites
- 0285US9796683B2Tetrasubstituted alkene compounds and their useEISAI R&D MAN CO LTD·Filed 2016·Granted Oct 24, 2017·6 cites·32 claims
- 0384US11352348B2Splicing modulator antibody-drug conjugates and methods of useEISAI R&D MAN CO LTD·Filed 2020·Granted Jun 7, 2022·1 cites·25 claims
- 0484US9481669B2Pladienolide pyridine compounds and methods of useEISAI R&D MAN CO LTD·Filed 2015·Granted Nov 1, 2016·7 cites·46 claims
- 0584US8980850B2Administration of a NEDD8-activating enzyme inhibitor and hypomethylating agentMILLENNIUM PHARM INC·Filed 2012·Granted Mar 17, 2015·6 cites·30 claims
- 0682US10889866B2Splice variants associated with neomorphic SF3B1 mutantsEISAI R&D MAN CO LTD·Filed 2016·Granted Jan 12, 2021·2 cites·18 claims
- 0777US11945807B2Splicing modulator antibody-drug conjugates and methods of useEISAI R&D MAN CO LTD·Filed 2022·Granted Apr 2, 2024·0 cites·24 claims
- 0874US9827246B2Biomarkers of response to NAE inhibitorsMILLENNIUM PHARM INC·Filed 2012·Granted Nov 28, 2017·3 cites·33 claims
- 0970US12172986B2Splicing modulator antibody-drug conjugates and methods of useEISAI R&D MAN CO LTD·Filed 2019·Granted Dec 24, 2024·0 cites·46 claims
- 1063US11761045B2Splice variants associated with neomorphic SF3B1 mutantsEISAI R&D MAN CO LTD·Filed 2020·Granted Sep 19, 2023·0 cites·25 claims
- 1162US2024226098A1Compounds and methods for modulating splicingREMIX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1262US2024190879A1Fused bicyclic compounds useful for modulating nucleic acid splicingREMIX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1362US2023365566A1Heterocyclic amides and their use for modulating splicingREMIX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1460US2025109140A15-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseasesREMIX THERAPUTICS INC·Filed 2023·Application pending·0 cites
- 1559US2025082633A1Compounds and methods for modulating splicingREMIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1659US2023365526A1Pyridazine derivatives for modulating nucleic acid splicingREMIX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1759US2023140983A1Pyridazine derivatives for modulating nucleic acid splicingREMIX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1859US2025326748A1Compounds and methods for modulating splicingREMIX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1959US2025092065A12-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseasesREMIX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2058US2024287097A1Compounds and methods for modulating splicingREMIX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2158US2023159496A1Compounds and methods for modulating splicingREMIX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2258US2024366612A1Compounds and methods for modulating nucleic acid splicingREMIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2358US2024279239A1Compounds and methods for modulating splicingREMIX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2458US2025332173A1Compounds and methods for modulating nucleic acid splicingREMIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2557US2024400584A1Compounds and methods for modulating splicingREMIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2657US2024409536A1Compounds and methods for modulating splicingREMIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2757US2024368163A1Compounds and methods for modulating splicingREMIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2857US2025333397A1Compounds and methods for modulating splicingREMIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2957US2025154169A1Compounds and methods for modulating splicingREMIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3057US2023167093A1Compounds and methods for modulating splicingREMIX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3157US2020361915A1Solid state form of pladienolide pyridine compounds and methods of useEISAI R&D MAN CO LTD·Filed 2020·Application pending·0 cites
- 3256US10745387B2Crystalline form of (2S,3S,6S,7R,10R,E)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(piridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl-4-methylpiperazine-1-carboxylate and methods of use thereofEISAI R&D MAN CO LTD·Filed 2016·Granted Aug 18, 2020·0 cites·26 claims
- 3354US11357769B2Drug combinations for reducing cell viability and/or cell proliferationEISAI R&D MAN CO LTD·Filed 2017·Granted Jun 14, 2022·0 cites·29 claims
- 3452US2024239811A15-(5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the tREMIX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3552US2024002375A12-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treREMIX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3652US2024018522A1Oligonucleotides useful for modulation of splicingREMIX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3751US10953013B2Biomarkers of response to NAE inhibitorsMILLENNIUM PHARM INC·Filed 2016·Granted Mar 23, 2021·0 cites·12 claims
- 3851US2015030601A1E1 enzyme mutants and uses thereofMILLENNIUM PHARM INC·Filed 2012·Application pending·0 cites
- 3950US2018141913A1Tetrasubstituted alkene compounds and their useEISAI R&D MAN CO LTD·Filed 2017·Application pending·0 cites
- 4050US2020255415A1Tetrasubstituted alkene compounds and their use for the treatment of breast cancerEISAI R&D MAN CO LTD·Filed 2017·Application pending·0 cites
- 4150US2015366886A1Administration of nedd8-activating enzyme inhibitor and hypomethylating agentMILLENNIUM PHARM INC·Filed 2015·Application pending·0 cites
- 4249US10851065B2Tetrasubstituted alkene compounds and their useEISAI R&D MAN CO LTD·Filed 2017·Granted Dec 1, 2020·0 cites·20 claims
- 4349US2023148184A1Compounds and methods for modulating splicingREMIX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4448US2023142338A1Thiophenyl derivatives useful for modulating nucleic acid splicingREMIX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4545US11833119B2Combination therapies for the treatment of hepatocellular carcinomaEISAI R&D MAN CO LTD·Filed 2019·Granted Dec 5, 2023·0 cites·18 claims
- 4645US2017107579A1E1 enzyme mutants and uses thereofMILLENNIUM PHARM INC·Filed 2016·Application pending·0 cites
- 4744US2019175598A1Combination therapies for the treatment of hepatocellular carcinomaEISAI R&D MAN CO LTD·Filed 2017·Application pending·0 cites
- 4839US11524009B2Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of useEISAI R&D MAN CO LTD·Filed 2018·Granted Dec 13, 2022·0 cites·34 claims
- 4938US2019337921A1Tetrasubstituted alkene compounds and their useEISAI R&D MAN CO LTD·Filed 2017·Application pending·0 cites
- 5033US11083722B2Combination therapies for the treatment of breast cancerEISAI R&D MAN CO LTD·Filed 2018·Granted Aug 10, 2021·0 cites·22 claims
Join the waitlist — get patent alerts
Get an alert when Peter Smith files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →